SEMA3A and neoplasm: The RNAseq analysis of four null cell PitNETs and four silent subtype III PitNETs which were more clinically aggressive, demonstrated altered gene expression in tumor microenvironment and immuno-surveillance regulation, e.g., arginase type II (ARG2), semaphorin-3A (SEMA3A), and some HLA genes [103].